17 Oct 2017 --- Researchers have identified a region of the genome that regulates vitamin D activation in the kidneys, opening the door for more sophisticated treatments of diseases, including bone and immune disorders, involving vitamin D. The results of this research will be published in the October 20 issue of the Journal of Biological Chemistry.
Vitamin D is essential for building bones, the American Society for Biochemistry and Molecular Biology (ASBMB) press release notes. Inactive vitamin D obtained from the diet or produced in the skin is converted to its active form, calcitriol, in the kidneys.
Calcitriol can also be produced in other parts of the body, including skin cells and immune cells. In these non-kidney sites, calcitriol seems to serve a completely different purpose: it appears to play no role in regulation of minerals, and its production is induced by inflammation rather than by the hormones that control calcitriol synthesis in the kidneys.
Understanding the function of non-kidney calcitriol production and its connection to inflammatory diseases, ranging from multiple sclerosis to arthritis, is of great interest to a number of biomedical researchers, who would like to know whether and how vitamin D could potentially be used to treat these diseases.
However, research in this area has not been helped by the inability to separately study the pathways controlling kidney and non-kidney vitamin D activation.
Engineering helps focus on vitamin D activation A group of researchers at the University of Wisconsin, overseen by J. Wesley Pike, have now overcome this hurdle by using CRISPR/Cas engineering to produce mice with kidney-specific control of vitamin D activation.
“Through the creation of these mice, we can turn off endocrine regulation of [calcitriol] production exclusively in the kidney,” says Mark Meyer, the research associate who led the new study. “By doing so, we can focus further on the inflammatory regulation of [calcitriol].”
Calcitriol production is carried out by the enzyme CYP27B1, but the genomic regions that the team deleted in the experimental mice are far away from the gene encoding this enzyme. Rather, the researchers deleted what's known as enhancer regions for the Cyp27b1 gene. These regions of DNA bind to specific proteins controlled by the hormones involved in vitamin D regulation, causing the genomic DNA to rearrange in a way that enhances production of CYP27B1.
Importantly, deleting these regions affected the response of vitamin D activation to hormones, but not to inflammation-related molecules, indicating that these regions were key to allowing researchers to separately study the two types of calcitriol production.
While the long-term goal of the team is to understand the function of calcitriol in inflammatory diseases, identifying the kidney-specific enhancer region of the genome is already yielding insights into the mechanisms involved in bone disorders.
Meyer describes the work of a clinician collaborator who, in aiming to understand pediatric skeletal disorders, is examining his patients for mutations in the same enhancer regions identified in the mice.
“That [information] might be able to tell that particular clinician about which treatment course might be most appropriate for that individual,” Meyer says. For example, many skeletal disorders are treated with calcium and vitamin D supplements, but patients with mutations in regions involved in vitamin D regulation might actually be harmed by calcium supplementation.
The ASBMB study is the latest to confirm the benefits of vitamin D. The versatile vitamin has been linked to better child development and improved public health in Ireland.
Vitamin D was also a hot topic at Vitafoods 2017 during a discussion of “silver consumers,” and recent product launches with the vitamin include Cambridge Commodities’ VitaShroom mushroom-based vitamin D powder.
20 Apr 2018 –
Fermentalg, a French supplier of microalgae for ...
13 Apr 2018 –
8 --- CJ CheilJedang is making plans to build a ...
12 Apr 2018 –
DSM has pre-announced better-than-expected ...
09 Apr 2018 –
Novartis has entered into an agreement and plan ...
27 Mar 2018 –
GlaxoSmithKline (GSK) has reached an agreement ...